Xenon Pharmaceuticals Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ian C. Mortimer
- Full Time Employees
- 364
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3650 Gilmore Way Burnaby BC Canada V5G 4W8
- IPO Date
- Nov 5, 2014
- CIK
- 0001582313
- Website
- xenon-pharma.com
- Similar Companies
- Business
- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company founded in 1996 and headquartered in Burnaby, British Columbia, Canada, with additional offices in Boston, Massachusetts, engages in the discovery, clinical development, and commercialization of novel therapeutics targeting neurological and psychiatric disorders through ion channel modulation. The company advances a differentiated pipeline led by its flagship product candidate azetukalner, a novel, potent, selective Kv7 potassium channel opener in multiple Phase 3 clinical trials for focal onset seizures (X-TOLE2, X-TOLE3), primary generalized tonic-clonic seizures (X-ACKT), major depressive disorder (X-NOVA2, X-NOVA3), and bipolar depression (X-CEED); early-stage wholly-owned programs include XEN1120, a Kv7 potassium channel opener in Phase 1 for pain, and XEN1701, a Nav1.7 sodium channel inhibitor in Phase 1 for pain, alongside undisclosed preclinical Kv7 openers for epilepsy, pain, and psychiatry, Nav1.7 inhibitors for pain, and Nav1.1 sodium channel openers for Dravet syndrome. It also maintains a partnered program with Neurocrine Biosciences for NBI-921355 (formerly XEN901), a selective Nav1.2/1.6 sodium channel inhibitor in Phase 1 for epilepsy. Xenon serves patients with high unmet needs in epilepsy, depression, bipolar disorder, pain, and related neuropsychiatric conditions across North America and global clinical trial sites. Recent developments include completion of patient randomization in the Phase 3 X-TOLE2 trial for focal onset seizures with topline data expected in early 2026, ongoing recruitment in X-NOVA2/3 for major depressive disorder and X-CEED for bipolar depression, presentation of new long-term safety and efficacy data for azetukalner from the X-TOLE open-label extension at the American Epilepsy Society Annual Meeting in December 2025, and maintenance of a strong cash position of $555.3 million as of September 30, 2025, anticipated to fund operations into 2027 amid elevated R&D expenses for late-stage programs.
Company News
Xenon to Present at Wells Fargo Healthcare Conference
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
BlackRock Inc. Invests $454.06 Million in Xenon Pharmaceuticals Inc. $XENE
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity
Xenon Pharmaceuticals Q2 Earnings Call Highlights
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
Xenon Reports Q2 2026 Financial Results and Provides Business Update
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon to Report Q2 2026 Financial Results on August 6, 2026
Bank of New York Mellon Corp Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE
64,563 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Castleark Management LLC
Xenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial Execution
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript